The benefits of finasteride for hirsute women with polycystic ovary syndrome or idiopathic hirsutism

References

• Barbieri RL. Hyperandrogenic disorders. Clin Obstet Gynecol 33:640–54
   Google Scholar
• Wagner RF. Jr. Physical methods for the manage-ment of hirsutism. Cutis 1990;45:319–21
   Google Scholar
• Khoury MY, Baracat EC, Pardini DP, et al. Serum levels of androstanediol glucuronide, total testos-terone, and free testosterone in hirsute women. Fertil Steril 1994;62:76–80
   PubMed Web of Science ®Google Scholar
• Lima MF, Nunes MG, Bonduki CE, et al. The ACTH test in the diagnosis of hirsutism. Rev Paul Med 1997;115:1403–5
   Google Scholar
• Rabinowitz S, Cohen R, Le Roith HD. Anxiety and hirsutism. Psychol Rep 1983;53:827–30
   PubMed Web of Science ®Google Scholar
• colak R, Kelestimur F, Unlühizarci K, et al. A comparison between the effects of low dose (114) and standard dose (25014) ACTH stimulation tests on adrenal p450c17a enzyme activity in women with polycystic ovary syndrome. Eur J Endocrinol 2002;147: 473–7
   Google Scholar
• Gokmen O, Senoz S, Gulekli B, et al. Comparison of four different treatment regimes in hirsutism related to polycystic ovary syndrome. Gynecol Endocrinol 1996;10:249–55
   PubMed Web of Science ®Google Scholar
• Motta EL, Baracat EC, Haidar MA, et al. Ovarian activity before and after gonadal suppression by GnRH-a in patients with polycystic ovary syndrome, hyperandrogenism, hyperinsulinism and acanthosis nigricans. Rev Assoc Med Bras 1998; 44:94–8
   PubMedGoogle Scholar
• Pazos F, Escobar-Morreale HF, Balsa J, et al. Prospective randomized study comparing the long-acting gonadotropin-releasing hormone agonist triptorelin, flutamide, and cyproterone acetate, used in combination with an oral contra-ceptive, in the treatment of hirsutism. Fertil Steril 1999;71:122–8
   PubMed Web of Science ®Google Scholar
• Isik AZ, Gokmen O, Zeyneloglu HB, et al. Low dose ketoconazole is an effective and a relatively safe alternative in the treatment ofhirsutism. Aust N Z J Obstet Gynaecol 1996;36:487–9
   PubMed Web of Science ®Google Scholar
• Spritzer PM, Lisboa KO, Mattiello S, et al. Spironolactone as a single agent for long-term therapy of hirsute patients. Clin Endocrinol (Oxj) 2000;52:587–94
   PubMed Web of Science ®Google Scholar
• Van Wayjen RG, Van den Ende A. Experience in the long-term treatment of patients with hirsutism and/or acne with cyproterone acetate-containing preparations: efficacy, metabolic and endocrine effects. Exp Clin Endocrinol Diabetes 1995;103: 241–51
   PubMed Web of Science ®Google Scholar
• Muderris II, Bayram F, Sahin Y, et al. Comparison between two doses of flutamide (250 mg/d and 500 mg/d) in the treatment of hirsutism. Fertil Steril 1997;68:644–7
   PubMed Web of Science ®Google Scholar
• Rittmaster RS. Finasteride. N Engl J Med 1994; 330:120–5
   PubMed Web of Science ®Google Scholar
• Stoner E. The clinical development of a 5-a reductase inhibitor, finasteride. J Steroid Biochem Mol Biol 1990;37:375–8
   PubMed Web of Science ®Google Scholar
• Randall VA. Androgens and human hair growth. Clin Endocrinol 1994;40:439–57
   PubMed Web of Science ®Google Scholar
• Rittmaster RS. Androgen conjugates: physiology and clinical significance. Endocrinol Res 1993; 14:121
   Google Scholar
• Chen W, Zouboulis CC, Orfanos CE. 5 alpha reductase system and its inhibitors. Recent development and its perspective in treating androgen-dependent skin disorders. Dermatology 1996;193: 177–84
   Google Scholar
• Spinucci G, Pas quali R. La finasterida: un nuovo farmaco nel trattamento dell’irsurismo e dell’alopecia androgenica maschile? Clin Ter 1996; 147:305–15
   PubMedGoogle Scholar
• Castello R, Tosi F, Perrone F, et al. Outcome of long-term treatment with the 5 alpha reductase inhibitor finasteride in idiopathic hirsutism: clinical and hormonal effects and 1 year course of therapy and 1 year follow up. Fertil Steril 1996;66:734–40
   PubMed Web of Science ®Google Scholar
• Ciotta L, Cianci A, Calogero AE, etal. Clinical and endocrine effects of finasteride, a 5-a reductase inhibitor, in women with idiopathic hirsutism. Fertil Steril 1995;64:299–306
   PubMed Web of Science ®Google Scholar
• Moghetti P, Castello R, Chiara M, et al. Clinical and hormonal effects of the 5-a reductase inhibitor finasteride in idiopathic hirsutism. J Clin Endocrinol Metab 1994;79:1115–21
   PubMed Web of Science ®Google Scholar
• Tolino A, Petroni A, Sarnacchiaro F, et al. Finasteride in the treatment of hirsutism: new therapeutic perspectives. Fertil Steril 1996;66:61–5
   PubMed Web of Science ®Google Scholar
• Tenover JS, Stoner E, Rittmaster RS, et al. Effects of finasteride (MK-906), a 5-a reductase inhibitor, on circulating androgens in male volunteers.J Clin
   Google Scholar
• Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440–8
   PubMed Web of Science ®Google Scholar
• Siegel S, Castellan NJ Jr. Nonparametric Statistics, 2nd edn. New York: McGraw-Hill, 1988
   Google Scholar
• Hollander M, Wolfe DA. Nonparametric Statistical Methods. New York: John Wiley & Sons, 1973
   Google Scholar
• Landis JR, Kock GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159–74
   PubMed Web of Science ®Google Scholar
• Gormley GJ. Finasteride: a clinical review. Biomed Pharmacol 1995;49:319–24
   PubMed Web of Science ®Google Scholar
• Tremblay RR. Treatment of hirsutism with spironolactone. J Clin Endocrinol Metab 1986;5: 363–71
   Web of Science ®Google Scholar
• Hammerstein J, Meckies J, Leo-Rossberg I. Use of cyproterone acetate (CPA) in the treatment of acne, hirsutism and virilism. J Steroid Biochem 1975; 75:827–36
   Google Scholar
• Tolmo A, Petrone A, Sarnacchiaro F, et al. Finasteride in the treatment of hirsutism: new therapeutic perspectives. Fertil Steril 1996;66:61–5
   PubMed Web of Science ®Google Scholar
• Sahin Y, Bayram F, Kelestimur F, et al. Compari-son of cyproterone acetate plus ethinyl estradiol and finasteride in the treatment of hirsutism. J Endocrinol Invest 1998;21:348–52
   PubMed Web of Science ®Google Scholar
• Sahin Y, Dilber S, Kelestimurm F. Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism. Fertil Steril 2001;75: 496–500
   Google Scholar
• Falsetti L, Gamb era A, Platto C, et al. Management of hirsutism. Am J Clin Dermatol 2000;1:89–99
   PubMedGoogle Scholar
• Serafini P, Lobo RA. Increased 5-a reductase activity in idiopathic hirsutism. Fertil Steril 1985; 43:74–8
   PubMed Web of Science ®Google Scholar
• Venturoli S, Marescalchi O, Colombo FM, et al. A prospective randomized trial comparing low-dose flutamide, finasteride, ketoconozole and cyproterone acetate—estrogen regimens in the treatment of hirsutism. J Clin Endocrinol Metab 1999;84:1304–10
   PubMed Web of Science ®Google Scholar
• Falsetti L, Gambera A, Legrenzi L, et al. Compari-son of finasteride and flutamide in the treatment of hirsutism. Eur J Endocrinol 1999;141:361–7
   PubMed Web of Science ®Google Scholar